BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
-6.77%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$23.1B
AUM Growth
+$23.1B
(-13%)
Cap. Flow
-$142M
Cap. Flow
% of AUM
-0.62%
Top 10 Holdings %
Top 10 Hldgs %
80.48%
Holding
138
New
11
Increased
23
Reduced
15
Closed
12
Top Buys
| 1 |
Immunocore
IMCR
|
$107M |
| 2 |
Instil Bio
TIL
|
$97.7M |
| 3 |
TLIS
Talis Biomedical Corporation Common Stock
TLIS
|
$97.3M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$93.6M |
| 5 |
Design Therapeutics
DSGN
|
$43M |
Top Sells
Sector Composition
| 1 | Healthcare | 97.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
DBVT
26
DBV Technologies
DBVT
$250M
| $77.9M | 0.34% |
14,614,264
| – | – |
|
27
Nurix Therapeutics
NRIX
$719M
| $76.3M | 0.33% |
2,454,082
+665,161
| +37% | +$20.7M |
|
28
Kymera Therapeutics
KYMR
$3.01B
| $76.1M | 0.33% |
1,959,211
| – | – |
|
29
Rhythm Pharmaceuticals
RYTM
$6.96B
| $74M | 0.32% |
3,479,873
+1,165,000
| +50% | +$24.8M |
|
30
Insmed
INSM
$30.6B
| $73.4M | 0.32% |
2,156,001
| – | – |
|
31
Apellis Pharmaceuticals
APLS
$3.52B
| $71.8M | 0.31% |
1,674,004
+777,453
| +87% | +$33.4M |
|
32
Neurocrine Biosciences
NBIX
$13.9B
| $65.8M | 0.29% |
676,975
| – | – |
|
33
Krystal Biotech
KRYS
$4.36B
| $58.6M | 0.25% |
760,412
+61,538
| +9% | +$4.74M |
|
|
FMTX
34
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $56.7M | 0.25% |
2,024,876
| – | – |
|
|
HZNP
35
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $55.1M | 0.24% |
599,110
| – | – |
|
|
BCEL
36
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $54.2M | 0.23% |
3,532,760
| – | – |
|
37
Zymeworks
ZYME
$1.07B
| $54M | 0.23% |
1,708,472
| – | – |
|
|
ADAP
38
Adaptimmune Therapeutics
ADAP
$14.7M
| $52.2M | 0.23% |
9,830,877
| – | – |
|
39
Kiniksa Pharmaceuticals
KNSA
$2.61B
| $51.8M | 0.22% |
2,799,577
| – | – |
|
40
Ultragenyx Pharmaceutical
RARE
$3.08B
| $50.6M | 0.22% |
444,444
| – | – |
|
41
Neurogene
NGNE
$278M
| $47M | 0.2% |
3,821,740
| – | – |
|
42
Immatics
IMTX
$676M
| $44.8M | 0.19% |
3,992,756
+2,187,731
| +121% | +$24.5M |
|
|
43
Design Therapeutics
DSGN
$332M
| $43M | 0.19% |
+1,436,636
| New | +$43M |
|
|
ACHL
44
DELISTED
Achilles Therapeutics plc American Depositary Shares
ACHL
| $42.9M | 0.19% |
+2,591,366
| New | +$42.9M |
|
45
Merus
MRUS
$5.06B
| $42.6M | 0.18% |
2,037,469
| – | – |
|
46
Verastem
VSTM
$576M
| $42M | 0.18% |
17,019,294
+6,875,255
| +68% | +$17M |
|
47
BioAtla
BCAB
$28.5M
| $41.9M | 0.18% |
825,000
| – | – |
|
48
Altimmune
ALT
$327M
| $39M | 0.17% |
2,758,518
+874,067
| +46% | +$12.4M |
|
49
Fulgent Genetics
FLGT
$675M
| $38.7M | 0.17% |
401,016
-94,557
| -19% | -$9.14M |
|
50
Protagonist Therapeutics
PTGX
$3.67B
| $37.2M | 0.16% |
1,436,192
| – | – |
|